We performed a comprehensive systematic search of PubMed, MEDLINE and EMBASE databases following the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) guidelines. We used keywords combined with Boolean operators to increase search sensitivity and specificity. From those patients who chose “Femoral”, the subsequent question “What reasons influenced your answer?” was answered as following: pain (55.5%), bruising (22.2%), complications (11.1%), recovery time (22.2%), mobility (33.3%), failure of the other approach (22.2%) and comfort of puncturing the respective area (0%). When those who answered “no preference” were further questioned “why?”, 75% answered “it’s a physicians’ decision” and 25% answered “similar experiences with both radial and femoral”. 

**Conclusions** At our institution, most patients preferred transradial over transfemoral approach. Most common reasons included pain, recovery time and bruising. Although the effectiveness and safety of transradial approach for non-diagnostic neurointervention remains uncertain and continues to technically evolve, it may be the best option for diagnostic angiograms considering the patients’ preference.

**Disclosures** J. Cappuzzo: None. A. Aguirre: None. A. Monteiro: None. K. Vakharia: None. N. Ruggiero: None. M. Waqas: None. R. Dossani: None. J. Davies: 1; C. National Center for Advancing Translational Sciences of the National Institutes of Health under award number K23TR001928 to the University at Buffalo. A. Siddiqui: 2; C. Amnis Therapeutics, Boston Scientific, Canon Medical Systems USA Inc., Cerebrotech Medical Systems Inc., Cerenovus, Corindus Inc., Endostream Medical Ltd., Impervive Care, Inc. Integrative Life Sciences. C. 4; C. Adona Medical, Inc. Amnis Therapeutics, (Purchased by Boston Scientific October 2017), Blink TBI Inc., Buffalo Technology Partners Inc., Cerebrotech Medical Systems, Inc., Cognition Medical, Endostrea. E. Levy: 2; C. Claret Medical, GLG Consulting, Guidepoint Global, Imperative Care, Medtronic, Rebound, StimMed; 4; C. NeXtGen Biologics, RAPID Medical, Claret Medical, Cognition Medical, Imperative Care (formerly the Stroke Project), Rebound Therapeutics, StimMed, Three Rivers Medical. F. Almayman: None. J. Cappuzzo: None. J. Nie: None. J. Davies: 1; C. National Center for Advancing Translational Sciences of the National Institutes of Health under award number KL2TR001413 to the University at Buffalo. 2; C. Medtronic. K. Snyder: 2; C. Canon Medical Systems Corporation, Penumbra Inc., Medtronic, and Jacobs Institute. E. Levy: 2; C. Claret Medical, GLG Consulting, Guidepoint Global, Imperative Care, Medtronic, Rebound, StimMed; 4; C. NeXtGen Biologics, RAPID Medical, Claret Medical, Cognition Medical, Imperative Care (formerly the Stroke Project), Rebound Therapeutics, StimMed, Three Rivers Medical; A. Siddiqui: 2; C. Amnis Therapeutics, Boston Scientific, Canon Medical Systems USA Inc., Cerebrotech Medical Systems Inc., Cerenovus, Corindus Inc., Endostream Medical Ltd., Imperative Care, Inc. Integrative Life Sciences. C. 4; C. Adona Medical, Inc. Amnis Therapeutics, (Purchased by Boston Scientific October 2017), Blink TBI Inc., Buffalo Technology Partners Inc., Cerebrotech Medical Systems, Inc., Cognition Medical, Endostrea.

**Background** Management of acute basilar artery occlusion (BAO) remains a challenge, carrying high morbidity and mortality rates. Most evidence about BAO management comes from observational studies evaluating either intra-arterial therapies (IAT) or standard medical treatment (SMT). The optimal modality has not been determined.

**Methods** We performed a systematic review of all acute BAO studies published between January 2000 and October 2020. A pooled-analysis was performed to compare IAT and SMT.

**Results** Data from 4616 patients were pooled (IAT=3834, SMT=782). IAT had higher rates of good-outcome (31.7%) vs. 20.6%; P<0.001), moderate-outcome (44.4% vs. 18.6%; P<0.001), and lower mortality (33.2% vs. 45.3%; P<0.001). Unadjusted odds ratios (ORs) for good-outcome (OR 1.91, 95%confidence interval [CI] 1.56-2.33), and moderate-outcome (OR 2.68, 95%CI 2.17-3.32) significantly favored IAT, whereas mortality (OR 0.55, 95% CI 0.47-0.64) significantly favored SMT. After adjustments for age and National Institutes of Health Stroke Scale (NIHSS) score, ORs for good-outcome (adjusted OR [adjOR] 1.14, 95%CI 0.15-8.48), moderate-outcome (adjOR 1.75, 95%CI 0.22-14.08) and mortality (adjOR 1.39, 95%CI 0.38-5.11) did not significantly favor any modality. In a secondary analysis including only studies within the stent-retriever thrombectomy era (2009-2020), adjusted ORs for good-outcome (adjOR 2.51, 95%CI 1.01-6.19) significantly favored IAT, whereas moderate-outcome (adjOR 1.67, 95%CI 0.84-3.34) and mortality (adjOR 0.55, 95%CI 0.19-1.61) did not significantly favor any modality.

**Conclusions** Pooled-analysis showed superior outcomes for IAT. In the stent-retriever thrombectomy era, the odds of good outcome remain significant even after adjustments for age and NIHSS score, but randomized trials are needed to establish best management.

**Disclosures** A. Monteiro: None. M. Waqas: None. H. Rai: None. A. Baig: None. R. Dossani: None. F. Almayman: None. J. Cappuzzo: None. J. Nie: None. J. Davies: 1; C. National Center for Advancing Translational Sciences of the National Institutes of Health under award number KL2TR001413 to the University at Buffalo. 2; C. Medtronic. K. Snyder: 2; C. Canon Medical Systems Corporation, Penumbra Inc., Medtronic, and Jacobs Institute. E. Levy: 2; C. Claret Medical, GLG Consulting, Guidepoint Global, Imperative Care, Medtronic, Rebound, StimMed; 4; C. NeXtGen Biologics, RAPID Medical, Claret Medical, Cognition Medical, Imperative Care (formerly the Stroke Project), Rebound Therapeutics, StimMed, Three Rivers Medical; A. Siddiqui: 2; C. Amnis Therapeutics, Boston Scientific, Canon Medical Systems USA Inc., Cerebrotech Medical Systems Inc., Cerenovus, Corindus Inc., Endostream Medical Ltd., Imperative Care, Inc. Integrative Life Sciences. C. 4; C. Adona Medical, Inc. Amnis Therapeutics, (Purchased by Boston Scientific October 2017), Blink TBI Inc., Buffalo Technology Partners Inc., Cerebrotech Medical Systems, Inc., Cognition Medical, Endostrea.

**Introduction** Acute posterior cerebral artery (aPCAO) accounts for 5-10% of all ischemic strokes and can lead to significant disability involving a varied range of neurological syndromes with visual and cognitive deficits. In spite of this significant burden, these patients were largely excluded or under-represented in the major randomized trials of mechanical thrombectomy (MT), and the benefit of this modality over medical therapy alone remains controversial and uncertain.

**Methods** We performed a comprehensive systematic search of Pubmed, MEDLINE and EMBASE databases following the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) guidelines. We used keywords combined with Boolean operators to increase search sensitivity and specificity: “posterior cerebral artery”; “thrombolysis”; “thrombectomy”. Patients were allocated to pooled groups based on the